Low-Grade Hepatic Steatosis Is Associated with Long-term Remission of Type 2 Diabetes Independent of Type of Bariatric-Metabolic Surgery

[1]  K. Cusi,et al.  A global view of the interplay between non-alcoholic fatty liver disease and diabetes. , 2022, The lancet. Diabetes & endocrinology.

[2]  B. Laferrère,et al.  Role of the Gut in the Temporal Changes of β-Cell Function After Gastric Bypass in Individuals With and Without Diabetes Remission. , 2021, Diabetes care.

[3]  J. Hjelmesæth,et al.  Gastric Bypass Versus Sleeve Gastrectomy in Type 2 Diabetes: Effects on Hepatic Steatosis and Fibrosis , 2021, Annals of Internal Medicine.

[4]  W. Ling,et al.  Pancreatic β-Cell Dysfunction Is Associated with Nonalcoholic Fatty Liver Disease , 2021, Nutrients.

[5]  F. Rubino,et al.  Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes , 2021, Diabetes Care.

[6]  V. Kristiansen,et al.  Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies , 2021, Journal of clinical medicine.

[7]  M. Roden,et al.  The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments , 2021, Nature Reviews Gastroenterology & Hepatology.

[8]  U. Teixeira,et al.  BYPASS VS. SLEEVE AND ITS EFFECTS IN NON-ALCOHOLIC FATTY LIVER DISEASE: WHAT IS THE BEST TECHNIQUE? , 2021, Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery.

[9]  P. Schauer,et al.  Presence of Liver Steatosis Is Associated With Greater Diabetes Remission After Gastric Bypass Surgery , 2020, Diabetes Care.

[10]  Daniel B. Jones,et al.  Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass , 2020, JAMA surgery.

[11]  L. Funk,et al.  Bariatric Surgery and Diabetes Treatment-Finding the Sweet Spot. , 2020, JAMA surgery.

[12]  A. Sharples,et al.  Systematic Review and Meta-Analysis of Randomised Controlled Trials Comparing Long-Term Outcomes of Roux-En-Y Gastric Bypass and Sleeve Gastrectomy , 2019, Obesity Surgery.

[13]  Z. Younossi,et al.  The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. , 2019, Journal of hepatology.

[14]  K. Cusi,et al.  From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options , 2019, JHEP reports.

[15]  F. Knop,et al.  Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects , 2019, World journal of hepatology.

[16]  M. Bessler,et al.  Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Achieve Similar Early Improvements in Beta-cell Function in Obese Patients with Type 2 Diabetes , 2019, Scientific Reports.

[17]  J. Y. Park.  Prediction of Type 2 Diabetes Remission after Bariatric or Metabolic Surgery , 2018, Journal of obesity & metabolic syndrome.

[18]  Benjamin S. Aribisala,et al.  Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery. , 2018, Cell metabolism.

[19]  F. Pattou,et al.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. , 2015, Gastroenterology.

[20]  S. Brethauer,et al.  Standardized outcomes reporting in metabolic and bariatric surgery. , 2015, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[21]  F. Nascimbeni,et al.  Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease , 2014, Alimentary pharmacology & therapeutics.

[22]  G. Wakabayashi,et al.  Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: Current and Potential Future Treatments , 2014, Front. Endocrinol..

[23]  N. Sattar,et al.  Type 2 diabetes as a disease of ectopic fat? , 2014, BMC Medicine.

[24]  P. Schauer,et al.  DiaRem score: external validation. , 2014, The lancet. Diabetes & endocrinology.

[25]  Benjamin S. Aribisala,et al.  Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol , 2011, Diabetologia.

[26]  H. Kim,et al.  Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[27]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[28]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[29]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.